Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is an open-label, long-term, multi-center multi-national post-marketing observational registry. The objective of this study is to monitor the long-term efficacy, safety, tolerability and quality of life outcomes associated with ziconotide (Prialt) and other analgesics utilized in the intrathecal (IT) management of severe chronic pain.
This is an observational non-interventional registry. All patients will sign and date an Informed Consent Form (ICF) before enrollment (Baseline Visit). Normal clinical practice will be followed. Patients will continue to follow their usual schedule of clinic visits as determined by their physician, during which information and patient-completed questionnaires will be collected (at scheduled intervals timed to coincide with pump refill).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ziconotide | No drug will be provided by the sponsor. Treatment decisions will be made by physicians independent of participation in the registry. IT analgesia may consist of ziconotide or any other drug used in IT therapy, including those used off-label as part of local clinical practice. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Average Overall Change From Baseline (Visit 1) in Visual Analog Scale of Pain Intensity (VASPI) | VASPI is a worldwide validated measure of pain intensity. A Visual Analog Score (VAS) for pain is determined by using a horizontal line, 100-millimeter (mm) in length, anchored by word descriptors at each end; "no pain" (0 mm) on the left end and "worst imaginable pain" (100 mm) on the right end. The participant was asked to mark on the line the point that they feel represents their current state of pain. A VAS for least pain (over last two weeks), usual pain (over last two weeks), and pain today was determined and averaged to derive the total VAS score ranging from 0 (no pain) to 100 (worst pain imaginable). A last observation carried forward (LOCF) dataset was used to account for missing data where First Visit data could be carried forward. | Month 8 (Visit 4), Month 12 (Visit 5), and Termination Visit (12 months after last participant was enrolled) |
| Measure | Description | Time Frame |
|---|---|---|
| Overall Change in Pain Severity and Pain Interference From Baseline (Visit 1) to Month 12 (Visit 5) | The Brief Pain Inventory-Short Form (BPI-SF) survey is made up of two dimensions: pain intensity/severity and pain interference, with each dimension containing specific items that are graded (e.g. mood, walking ability, relations with other people, enjoyment of life, etc.). Each item was graded on an 11-point Likert scale. The pain intensity/severity survey was used to measure pain severity, where 0 was "no pain" and 10 was "pain as bad as you can imagine" for each item listed. The pain interference survey scored each item on a scale, where 0 was "does not interfere" to 10 was "completely interferes". The change in pain severity and pain interference from Baseline (Visit 1) were calculated from the scores. |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in Primary Intrathecal Drug, Including Dose Adjustment and Intervals | Data for this outcome measure was collected as part of the participant's study visit, however was not analyzed as an efficacy endpoint for reporting. | 12 months after the last patient was enrolled |
| Change in the Actual Overall EuroQoL (EQ-5D) Health Score From First Visit to Month 12 and End of Study |
Inclusion Criteria
Patients will be eligible to enroll onto the registry if they have given informed consent and meet the following criteria:
All patients starting ziconotide (Prialt) should comply with the indications and warnings in the current approved version of the Summary of Product Characteristics (SmPC).
Exclusion Criteria
Patients who meet any of the following criteria will not be eligible to enroll in the registry:
Not provided
Not provided
Not provided
Patients that have a diagnosis of severe, chronic pain for which intrathecal infusion is indicated.
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Ziconotide Monotherapy | Participants who took ziconotide alone. |
| FG001 | Ziconotide Combination | Participants who took ziconotide in combination with another intrathecal (IT) therapy. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
| Baseline (Visit 1) to Month 12 (Visit 5) |
| Overall Change in Pain Severity and Pain Interference From Baseline (Visit 1) to Termination Visit | The BPI-SF survey is made up of two dimensions: pain intensity/severity and pain interference, with each dimension containing specific items that are graded (e.g. mood, walking ability, relations with other people, enjoyment of life, etc.). Each item was graded on an 11-point Likert scale. The pain intensity/severity survey was used to measure pain severity, where 0 was "no pain" and 10 was "pain as bad as you can imagine" for each item listed. The pain interference survey scored each item on a scale, where 0 was "does not interfere" to 10 was "completely interferes". The change in pain severity and pain interference from Baseline (Visit 1) were calculated from the scores. | Baseline (Visit 1) to Termination Visit (12 Months after last participant was enrolled) |
| Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE) | Safety assessments consisted of monitoring and recording all adverse events (AEs) and serious adverse events (SAEs), any therapeutic interventions including all drug therapies, vital signs, and creatine kinase (CK) if laboratory tests were taken by the physician as part of routine clinical practice. AEs were graded on a 3-point scale; 1) mild - discomfort noticed, but no disruption of normal daily activity, 2) moderate - discomfort sufficient to reduce or affect normal daily activity, 3) severe - incapacitating, with inability to work or to perform normal daily activity. A TEAE was defined as an adverse event (AE) with a start date on or after the date of the First Visit. Where a start date was missing, the AE was considered to be treatment-emergent. | From first dose up to 30 days after the last dose of study treatment, for up to approximately 4 years 4 months. |
The EQ-5D is a standardized instrument used to measure quality of life. It classifies health states across five domains: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each domain has three levels (no problems, some/moderate problems, extreme problems). A unique EQ-5D health state was defined by combining one level from each of the five dimensions. The response to the question of how good or bad the participant's health was today was given on a visual analogue scale of 0 to 100 millimeters (mm), where 0 meant the participant was in the worst imaginable health state today and 100 meant the participant was in the best imaginable health state today. The results for the Health Score were that of the calculated overall score of the five dimensions, where -0.594 is worst health and 1.00 is perfect health. Change is defined as change in actual from the First Visit. |
| Month 12 Visit, End of Study (Termination Visit) |
| FG002 | Other IT Monotherapy | Participants who took an IT therapy other than ziconotide. |
| FG003 | Other IT Combination | Participants who took two (or more) IT therapies in conjunction other than ziconotide. |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Safety population consisted of all participants who had at least one dose of an intrathecal (IT) therapy.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Ziconotide Monotherapy | Participants who took ziconotide alone. |
| BG001 | Ziconotide Combination | Participants who took ziconotide in combination with another intrathecal (IT) therapy. |
| BG002 | Other IT Monotherapy | Participants who took an IT therapy other than ziconotide. |
| BG003 | Other IT Combination | Participants who took two (or more) IT therapies in conjunction other than ziconotide. |
| BG004 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | Years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Average Overall Change From Baseline (Visit 1) in Visual Analog Scale of Pain Intensity (VASPI) | VASPI is a worldwide validated measure of pain intensity. A Visual Analog Score (VAS) for pain is determined by using a horizontal line, 100-millimeter (mm) in length, anchored by word descriptors at each end; "no pain" (0 mm) on the left end and "worst imaginable pain" (100 mm) on the right end. The participant was asked to mark on the line the point that they feel represents their current state of pain. A VAS for least pain (over last two weeks), usual pain (over last two weeks), and pain today was determined and averaged to derive the total VAS score ranging from 0 (no pain) to 100 (worst pain imaginable). A last observation carried forward (LOCF) dataset was used to account for missing data where First Visit data could be carried forward. | Intent-to-Treat (ITT) (LOCF) population included all participants who had at least one dose of an IT therapy. Total number of participants for the outcome measures (335) does not match the total number enrolled (219) due to participants switching between treatment arms as allowed per protocol. | Posted | Mean | Standard Deviation | Units on a scale | Month 8 (Visit 4), Month 12 (Visit 5), and Termination Visit (12 months after last participant was enrolled) |
|
|
| ||||||||||||||||||||||||||||||||||
| Secondary | Overall Change in Pain Severity and Pain Interference From Baseline (Visit 1) to Month 12 (Visit 5) | The Brief Pain Inventory-Short Form (BPI-SF) survey is made up of two dimensions: pain intensity/severity and pain interference, with each dimension containing specific items that are graded (e.g. mood, walking ability, relations with other people, enjoyment of life, etc.). Each item was graded on an 11-point Likert scale. The pain intensity/severity survey was used to measure pain severity, where 0 was "no pain" and 10 was "pain as bad as you can imagine" for each item listed. The pain interference survey scored each item on a scale, where 0 was "does not interfere" to 10 was "completely interferes". The change in pain severity and pain interference from Baseline (Visit 1) were calculated from the scores. | ITT LOCF population | Posted | Mean | Standard Deviation | Scores on a scale | Baseline (Visit 1) to Month 12 (Visit 5) |
| ||||||||||||||||||||||||||||||||||||
| Secondary | Overall Change in Pain Severity and Pain Interference From Baseline (Visit 1) to Termination Visit | The BPI-SF survey is made up of two dimensions: pain intensity/severity and pain interference, with each dimension containing specific items that are graded (e.g. mood, walking ability, relations with other people, enjoyment of life, etc.). Each item was graded on an 11-point Likert scale. The pain intensity/severity survey was used to measure pain severity, where 0 was "no pain" and 10 was "pain as bad as you can imagine" for each item listed. The pain interference survey scored each item on a scale, where 0 was "does not interfere" to 10 was "completely interferes". The change in pain severity and pain interference from Baseline (Visit 1) were calculated from the scores. | ITT LOCF population | Posted | Mean | Standard Deviation | Scores on a scale | Baseline (Visit 1) to Termination Visit (12 Months after last participant was enrolled) |
| ||||||||||||||||||||||||||||||||||||
| Secondary | Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE) | Safety assessments consisted of monitoring and recording all adverse events (AEs) and serious adverse events (SAEs), any therapeutic interventions including all drug therapies, vital signs, and creatine kinase (CK) if laboratory tests were taken by the physician as part of routine clinical practice. AEs were graded on a 3-point scale; 1) mild - discomfort noticed, but no disruption of normal daily activity, 2) moderate - discomfort sufficient to reduce or affect normal daily activity, 3) severe - incapacitating, with inability to work or to perform normal daily activity. A TEAE was defined as an adverse event (AE) with a start date on or after the date of the First Visit. Where a start date was missing, the AE was considered to be treatment-emergent. | Safety population included all participants who had at least one dose of an IT therapy. | Posted | Count of Participants | Participants | From first dose up to 30 days after the last dose of study treatment, for up to approximately 4 years 4 months. |
| |||||||||||||||||||||||||||||||||||||
| Other Pre-specified | Changes in Primary Intrathecal Drug, Including Dose Adjustment and Intervals | Data for this outcome measure was collected as part of the participant's study visit, however was not analyzed as an efficacy endpoint for reporting. | Data for this outcome measure was collected as part of the participant's study visit, however was not analyzed as an efficacy endpoint for reporting. | Posted | 12 months after the last patient was enrolled |
| |||||||||||||||||||||||||||||||||||||||
| Other Pre-specified | Change in the Actual Overall EuroQoL (EQ-5D) Health Score From First Visit to Month 12 and End of Study | The EQ-5D is a standardized instrument used to measure quality of life. It classifies health states across five domains: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each domain has three levels (no problems, some/moderate problems, extreme problems). A unique EQ-5D health state was defined by combining one level from each of the five dimensions. The response to the question of how good or bad the participant's health was today was given on a visual analogue scale of 0 to 100 millimeters (mm), where 0 meant the participant was in the worst imaginable health state today and 100 meant the participant was in the best imaginable health state today. The results for the Health Score were that of the calculated overall score of the five dimensions, where -0.594 is worst health and 1.00 is perfect health. Change is defined as change in actual from the First Visit. | ITT population. Missing items/values used in calculating the partially complete Health Score were imputed using last observation carried forward (LOCF). | Posted | Mean | Standard Deviation | Scores on a scale | Month 12 Visit, End of Study (Termination Visit) |
|
For each participant, from the first dose till 30 days after the last dose or up to the termination visit (which was 12 months after the last subject had been enrolled), or approximately 4 years.
The safety population included all participants who received at least one dose of an IT therapy. Treatment emergent adverse events (TEAEs) and serious adverse events were reported. Participants could switch IT therapies during the study, so AEs were assigned to the treatment taken at the time and date of the onset of the AE. This resulted in the possibility of a participant being counted in more than one therapy category.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Ziconotide Monotherapy | Participants who took ziconotide alone. | 3 | 83 | 26 | 83 | 59 | 83 |
| EG001 | Ziconotide Combination | Participants who took ziconotide in combination with another intrathecal (IT) therapy. | 26 | 114 | 51 | 114 | 70 | 114 |
| EG002 | Other IT Monotherapy | Participants who took an IT therapy other than ziconotide. | 7 | 67 | 24 | 67 | 34 | 67 |
| EG003 | Other IT Combination | Participants who took two (or more) IT therapies in conjunction other than ziconotide. | 12 | 71 | 30 | 71 | 43 | 71 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Death | General disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Pain | General disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| General Physical Health Deterioration | General disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Catheter Related Complication | General disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Pyrexia | General disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Chest Pain | General disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Oedema Peripheral | General disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Catheter Site Pain | General disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Disease Progression | General disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Drug Withdrawal Syndrome | General disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Extravasation | General disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Face Oedema | General disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Fatigue | General disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Generalised Oedema | General disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Infusion Site Mass | General disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Oedema | General disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Pneumonia | Infections and infestations | MedDRA (11.1) | Non-systematic Assessment |
| |
| Meningitis | Infections and infestations | MedDRA (11.1) | Non-systematic Assessment |
| |
| Urinary Tract Infection | Infections and infestations | MedDRA (11.1) | Non-systematic Assessment |
| |
| Catheter Related Infection | Infections and infestations | MedDRA (11.1) | Non-systematic Assessment |
| |
| Device Related Infection | Infections and infestations | MedDRA (11.1) | Non-systematic Assessment |
| |
| Sepsis | Infections and infestations | MedDRA (11.1) | Non-systematic Assessment |
| |
| Abscess | Infections and infestations | MedDRA (11.1) | Non-systematic Assessment |
| |
| Breast Cellulitis | Infections and infestations | MedDRA (11.1) | Non-systematic Assessment |
| |
| Bronchitis | Infections and infestations | MedDRA (11.1) | Non-systematic Assessment |
| |
| Cellulitis | Infections and infestations | MedDRA (11.1) | Non-systematic Assessment |
| |
| Escherichia Sepsis | Infections and infestations | MedDRA (11.1) | Non-systematic Assessment |
| |
| Gastroenteritis | Infections and infestations | MedDRA (11.1) | Non-systematic Assessment |
| |
| Implant Site Infection | Infections and infestations | MedDRA (11.1) | Non-systematic Assessment |
| |
| Infection | Infections and infestations | MedDRA (11.1) | Non-systematic Assessment |
| |
| Lobar Pneumonia | Infections and infestations | MedDRA (11.1) | Non-systematic Assessment |
| |
| Lower Respiratory Tract Infection | Infections and infestations | MedDRA (11.1) | Non-systematic Assessment |
| |
| Rectal Abscess | Infections and infestations | MedDRA (11.1) | Non-systematic Assessment |
| |
| Soft Tissue Infection | Infections and infestations | MedDRA (11.1) | Non-systematic Assessment |
| |
| Staphylococcal Infection | Infections and infestations | MedDRA (11.1) | Non-systematic Assessment |
| |
| Staphylococcal Skin Infection | Infections and infestations | MedDRA (11.1) | Non-systematic Assessment |
| |
| Wound Infection | Infections and infestations | MedDRA (11.1) | Non-systematic Assessment |
| |
| Lung Neoplasm Malignant | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.1) | Non-systematic Assessment |
| |
| Pancreatic Carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.1) | Non-systematic Assessment |
| |
| Neoplasm Malignant | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.1) | Non-systematic Assessment |
| |
| Breast Cancer Metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.1) | Non-systematic Assessment |
| |
| Colorectal Cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.1) | Non-systematic Assessment |
| |
| Non-small Cell Lung Cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.1) | Non-systematic Assessment |
| |
| Pancreatic Carcinoma Metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.1) | Non-systematic Assessment |
| |
| Bone Sarcoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.1) | Non-systematic Assessment |
| |
| Colorectal Cancer Metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.1) | Non-systematic Assessment |
| |
| Malignant Melanoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.1) | Non-systematic Assessment |
| |
| Metastases To Bone | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.1) | Non-systematic Assessment |
| |
| Metastases To Central Nervous System | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.1) | Non-systematic Assessment |
| |
| Metastases To Meninges | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.1) | Non-systematic Assessment |
| |
| Metastatic Malignant Melanoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.1) | Non-systematic Assessment |
| |
| Metastatic Uterine Cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.1) | Non-systematic Assessment |
| |
| Pancreatic Neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.1) | Non-systematic Assessment |
| |
| Renal Cancer Metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.1) | Non-systematic Assessment |
| |
| Medical Device Complication | Injury, poisoning and procedural complications | MedDRA (11.1) | Non-systematic Assessment |
| |
| Contusion | Injury, poisoning and procedural complications | MedDRA (11.1) | Non-systematic Assessment |
| |
| Device Dislocation | Injury, poisoning and procedural complications | MedDRA (11.1) | Non-systematic Assessment |
| |
| Hip Fracture | Injury, poisoning and procedural complications | MedDRA (11.1) | Non-systematic Assessment |
| |
| Excoriation | Injury, poisoning and procedural complications | MedDRA (11.1) | Non-systematic Assessment |
| |
| Fall | Injury, poisoning and procedural complications | MedDRA (11.1) | Non-systematic Assessment |
| |
| Overdose | Injury, poisoning and procedural complications | MedDRA (11.1) | Non-systematic Assessment |
| |
| Alcohol Poisoning | Injury, poisoning and procedural complications | MedDRA (11.1) | Non-systematic Assessment |
| |
| Device Connection Issue | Injury, poisoning and procedural complications | MedDRA (11.1) | Non-systematic Assessment |
| |
| Foot Fracture | Injury, poisoning and procedural complications | MedDRA (11.1) | Non-systematic Assessment |
| |
| Inadequate Analgesia | Injury, poisoning and procedural complications | MedDRA (11.1) | Non-systematic Assessment |
| |
| Poisoning | Injury, poisoning and procedural complications | MedDRA (11.1) | Non-systematic Assessment |
| |
| Procedural Pain | Injury, poisoning and procedural complications | MedDRA (11.1) | Non-systematic Assessment |
| |
| Road Traffic Accident | Injury, poisoning and procedural complications | MedDRA (11.1) | Non-systematic Assessment |
| |
| Suture Related Complication | Injury, poisoning and procedural complications | MedDRA (11.1) | Non-systematic Assessment |
| |
| Thermal Burn | Injury, poisoning and procedural complications | MedDRA (11.1) | Non-systematic Assessment |
| |
| Thoracic Vertebral Fracture | Injury, poisoning and procedural complications | MedDRA (11.1) | Non-systematic Assessment |
| |
| Wound Secretion | Injury, poisoning and procedural complications | MedDRA (11.1) | Non-systematic Assessment |
| |
| Confusional State | Psychiatric disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Depression | Psychiatric disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Anxiety | Psychiatric disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Hallucination | Psychiatric disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Mental Disorder | Psychiatric disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Agitation | Psychiatric disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Anxiety Disorder | Psychiatric disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Delirium | Psychiatric disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Drug Abuse | Psychiatric disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Hallucinations, Mixed | Psychiatric disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Hostility | Psychiatric disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Narcissistic Personality Disorder | Psychiatric disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Psychotic Disorder | Psychiatric disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Suicidal Ideation | Psychiatric disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Abdominal Pain | Gastrointestinal disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Constipation | Gastrointestinal disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Diarrhoea | Gastrointestinal disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Colitis | Gastrointestinal disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Duodenal Ulcer Haemorrhage | Gastrointestinal disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Gastritis | Gastrointestinal disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Haemorrhoids | Gastrointestinal disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Melaena | Gastrointestinal disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Oesophagitis | Gastrointestinal disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Subileus | Gastrointestinal disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Back Pain | Musculoskeletal and connective tissue disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Bone Pain | Musculoskeletal and connective tissue disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Arthritis | Musculoskeletal and connective tissue disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Foot Deformity | Musculoskeletal and connective tissue disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Groin Pain | Musculoskeletal and connective tissue disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Intervertebral Disc Protrusion | Musculoskeletal and connective tissue disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Muscular Weakness | Musculoskeletal and connective tissue disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Pseudarthrosis | Musculoskeletal and connective tissue disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Rotator Cuff Syndrome | Musculoskeletal and connective tissue disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Spinal Column Stenosis | Musculoskeletal and connective tissue disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Cerebral Haemorrhage | Nervous system disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Dysgeusia | Nervous system disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Head Titubation | Nervous system disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Hypersomnia | Nervous system disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Ischaemic Stroke | Nervous system disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Neuralgia | Nervous system disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Nystagmus | Nervous system disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Parosmia | Nervous system disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Sciatica | Nervous system disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Somnolence | Nervous system disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Speech Disorder | Nervous system disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Spinal Cord Compression | Nervous system disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Stupor | Nervous system disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Syncope | Nervous system disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Transient Ischaemic Attack | Nervous system disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Tremor | Nervous system disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Trigeminal Neuralgia | Nervous system disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Deep Vein Thrombosis | Vascular disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Hypertension | Vascular disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Shock Haemorrhagic | Vascular disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Circulatory Collapse | Vascular disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Peripheral Ischaemia | Vascular disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Thrombosis | Vascular disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Venous Occlusion | Vascular disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Pneumonia Aspiration | Respiratory, thoracic and mediastinal disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Acute Respiratory Failure | Respiratory, thoracic and mediastinal disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Asphyxia | Respiratory, thoracic and mediastinal disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Bronchial Secretion Retention | Respiratory, thoracic and mediastinal disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Chronic Obstructive Pulmonary Disease | Respiratory, thoracic and mediastinal disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Obstructive Airways Disorder | Respiratory, thoracic and mediastinal disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Pulmonary Embolism | Respiratory, thoracic and mediastinal disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Respiratory Failure | Respiratory, thoracic and mediastinal disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Cardiac Failure | Cardiac disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Atrial Fibrillation | Cardiac disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Left Ventricular Dysfunction | Cardiac disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Left Ventricular Failure | Cardiac disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Dehydration | Metabolism and nutrition disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Feeding Disorder | Metabolism and nutrition disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Hyperglycaemia | Metabolism and nutrition disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Hypoalbuminaemia | Metabolism and nutrition disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Malnutrition | Metabolism and nutrition disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Renal Failure | Renal and urinary disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Renal Failure Acute | Renal and urinary disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Urinary Incontinence | Renal and urinary disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Central Venous Catheterisation | Surgical and medical procedures | MedDRA (11.1) | Non-systematic Assessment |
| |
| Drug Therapy | Surgical and medical procedures | MedDRA (11.1) | Non-systematic Assessment |
| |
| Medical Device Removal | Surgical and medical procedures | MedDRA (11.1) | Non-systematic Assessment |
| |
| Nerve Block | Surgical and medical procedures | MedDRA (11.1) | Non-systematic Assessment |
| |
| Peripheral Nerve Decompression | Surgical and medical procedures | MedDRA (11.1) | Non-systematic Assessment |
| |
| Spinal Nerve Stimulator Implantation | Surgical and medical procedures | MedDRA (11.1) | Non-systematic Assessment |
| |
| Ovarian Cyst | Reproductive system and breast disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Pelvic Haemorrhage | Reproductive system and breast disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Pelvic Pain | Reproductive system and breast disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Prostatitis | Reproductive system and breast disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Cataract | Eye disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Diplopia | Eye disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Strabismus | Eye disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| C-reactive Protein Increased | Investigations | MedDRA (11.1) | Non-systematic Assessment |
| |
| International Normalised Ratio Increased | Investigations | MedDRA (11.1) | Non-systematic Assessment |
| |
| Weight Decreased | Investigations | MedDRA (11.1) | Non-systematic Assessment |
| |
| Anaemia | Blood and lymphatic system disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Neutropenia | Blood and lymphatic system disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Thrombocytopenia | Blood and lymphatic system disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Behcet's Syndrome | Immune system disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Hypersensitivity | Immune system disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Vertigo | Ear and labyrinth disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Biliary Dilatation | Hepatobiliary disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Skin Erosion | Skin and subcutaneous tissue disorders | MedDRA (11.1) | Non-systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Dizziness | Nervous system disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Memory Impairment | Nervous system disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Somnolence | Nervous system disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Hypoaesthesia | Nervous system disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Constipation | Gastrointestinal disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Diarrhoea | Gastrointestinal disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Dry Mouth | Gastrointestinal disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Oedema Peripheral | General disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Fatigue | General disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Muscular Weakness | Musculoskeletal and connective tissue disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Back Pain | Musculoskeletal and connective tissue disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Pain In Extremity | Musculoskeletal and connective tissue disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Confusional State | Psychiatric disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Insomnia | Psychiatric disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Hyperhidrosis | Skin and subcutaneous tissue disorders | MedDRA (11.1) | Non-systematic Assessment |
| |
| Weight Decreased | Investigations | MedDRA (11.1) | Non-systematic Assessment |
| |
| Vertigo | Ear and labyrinth disorders | MedDRA (11.1) | Non-systematic Assessment |
|
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Eisai Medical Services | Eisai Europe Ltd. | +44 (0)20 8600 1400 |
| ID | Term |
|---|---|
| D000377 | Agnosia |
| D059350 | Chronic Pain |
| ID | Term |
|---|---|
| D010468 | Perceptual Disorders |
| D019954 | Neurobehavioral Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D010146 | Pain |
Not provided
Not provided
| Male |
|
| Month 12 (Visit 5) |
|
| Termination Visit |
|
| OG003 | Other IT Combination | Participants who took two (or more) IT therapies in conjunction other than ziconotide. |
|
|
| OG003 | Other IT Combination | Participants who took two (or more) IT therapies in conjunction other than ziconotide. |
|
|
| Other IT Monotherapy |
Participants who took an IT therapy other than ziconotide. |
| OG003 | Other IT Combination | Participants who took two (or more) IT therapies in conjunction other than ziconotide. |
|
|
| Units | Counts |
|---|---|
| Participants |
|
| OG002 | Other IT Monotherapy | Participants who took an IT therapy other than ziconotide. |
| OG003 | Other IT Combination | Participants who took two (or more) IT therapies in conjunction other than ziconotide. |
|
|
| Title | Measurements |
|---|---|
|